bentamapimod
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01630252)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- c-Jun N-terminal kinase, JNKINHIBITOR
c-Jun N-terminal kinase, JNK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#CC(c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1)c1nc2ccccc2s1- Mol. weight
- 457.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545213 ↗
Also known as
- as602801
- as-602801
- as-602801
- bentamapimod
- bentamapimod
- bentamapimod
- pgl5001
- pgl5001
- pgl5001
- pgl-5001
- pgl-5001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01630252 | Phase 2 | Jun 1, 2012 | Gedeon Richter Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gedeon Richter Ltd. | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1